{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:19:10Z","timestamp":1791001150513,"version":"4.1.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"1-2","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Vaccines"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec><jats:title>Objectives:<\/jats:title><jats:p> The only human Lyme disease vaccine of LYMErix was voluntarily removed from the market in the United States in 2002 for a number of reasons. A new human Lyme disease vaccine is currently being developed. We would like any future approved human Lyme disease vaccine to be of interest and marketable to consumers. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> We surveyed 714 participants to determine variables associated with intentions to receive a Lyme disease vaccine. Predictor variables included demographics, protection motivational theory, Lyme disease knowledge, Lyme disease preventive behaviors, beliefs and perceived health. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> We found in multivariate linear regression analyses that Asian\/Asian American race\/ethnicity ( p &lt; 0.001), South Asian race\/ethnicity ( p = 0.01) and coping appraisal variables of response efficacy ( p &lt; 0.001) and self-efficacy ( p &lt; 0.001) were each significantly associated with increased intentions. The belief that vaccines are typically not safe was significantly associated with decreased intentions ( p = 0.03). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p> Asian\/Asian American and South Asian race\/ethnicities have a strong interest in receiving a Lyme disease vaccine. Although pharmaceutical companies may benefit by advertising a Lyme disease vaccine to Asian\/Asian Americans and South Asians, marketers need to address and use approaches to interest those from other race\/ethnicities. Also, marketers need to address the erroneous belief that vaccines are typically not safe in order to interest those with such beliefs to use a Lyme disease vaccine. <\/jats:p><\/jats:sec>","DOI":"10.1177\/2051013616629881","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T02:43:58Z","timestamp":1454640238000},"page":"3-14","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Intentions to receive a potentially available Lyme disease vaccine in an urban sample"],"prefix":"10.1177","volume":"4","author":[{"given":"Joshua","family":"Fogel","sequence":"first","affiliation":[{"name":"Department of Business Management, Brooklyn College of the City University of New York, 218A, 2900 Bedford Avenue, Brooklyn, NY 11210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kusz","sequence":"additional","affiliation":[{"name":"Department of Biology, Brooklyn College, Brooklyn, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,7,31]]},"reference":[{"key":"bibr1-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-225"},{"key":"bibr2-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.107"},{"key":"bibr3-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2007.05.013"},{"key":"bibr4-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.12.030"},{"key":"bibr5-2051013616629881","unstructured":"Centers for Disease Control and Prevention (2013) How many people get Lyme disease? Available at: http:\/\/www.cdc.gov\/lyme\/stats\/humanCases.html (accessed 17 February 2015)."},{"key":"bibr6-2051013616629881","unstructured":"Centers for Disease Control and Prevention (2014) Transmission. Available at: http:\/\/www.cdc.gov\/lyme\/transmission\/ (accessed 4 November 2014)."},{"key":"bibr7-2051013616629881","unstructured":"Centers for Disease Control and Prevention (2015) Lyme disease (Borrelia burgdorferi): 2011 case definition. Available at: http:\/\/wwwn.cdc.gov\/nndss\/conditions\/lyme-disease\/case-definition\/2011\/ (accessed 21 January 2016)."},{"key":"bibr8-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1006\/pmed.1999.0535"},{"key":"bibr9-2051013616629881","unstructured":"Francis J., Ecles M., Johnston M., Walker A., Grimshaw J., Foy R. (2004) Constructing questionnaires based on the theory of planned behaviour: a manual for health services researchers. Newcastle upon Tyne, UK: Centre for Health Services Research, University of Newcastle upon Tyne. Available at: http:\/\/openaccess.city.ac.uk\/1735\/ (accessed 24 April 2015)."},{"key":"bibr10-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-012-0389-1"},{"key":"bibr11-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1089\/vbz.2007.0221"},{"key":"bibr12-2051013616629881","volume-title":"IBM SPSS Statistics for Windows","author":"IBM Corp","year":"2011"},{"key":"bibr13-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.11.112"},{"key":"bibr14-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268806007096"},{"key":"bibr15-2051013616629881","doi-asserted-by":"publisher","DOI":"10.4278\/0890-1171-20.6.379"},{"key":"bibr16-2051013616629881","first-page":"81","volume-title":"Predicting Health Behaviour: Research and Practice with Social Cognition Models","author":"Norman P.","year":"2005"},{"key":"bibr17-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.590671.25"},{"key":"bibr18-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq116"},{"key":"bibr19-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1010594"},{"key":"bibr20-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024943"},{"key":"bibr21-2051013616629881","doi-asserted-by":"publisher","DOI":"10.4161\/hv.25250"},{"key":"bibr22-2051013616629881","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70110-5"}],"container-title":["Therapeutic Advances in Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2051013616629881","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2051013616629881","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2051013616629881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T07:01:22Z","timestamp":1740812482000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2051013616629881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":22,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1177\/2051013616629881"],"URL":"https:\/\/doi.org\/10.1177\/2051013616629881","relation":{},"ISSN":["2051-0144","2051-0136"],"issn-type":[{"value":"2051-0144","type":"print"},{"value":"2051-0136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}